Source comparison
Tesamorelin vs Egrifta — Same Compound, Different Branding
The question 'what's the difference between tesamorelin and egrifta' assumes two distinct compounds. In reality, Egrifta is the FDA-approved brand name for tesamorelin acetate. A 44-amino-acid synthetic growth hormone-releasing hormone (GHRH) analogue develope
This comparison does not assign a generated winner or score.
- The question 'what's the difference between tesamorelin and egrifta' assumes two distinct compounds. In reality, Egrifta is the FDA-approved brand name for tesamorelin acetate. A 44-amino-acid synthetic growth hormone-releasing hormone (GHRH) analogue developed by Theratechnologies. The molecule inside every Egrifta vial is tesamorelin. The distinction isn't chemical. It's regulatory and commercial. Egrifta received FDA approval in 2010 specifically for reducing excess abdominal fat in HIV patients with lipodystrophy, meaning it underwent Phase III clinical trials, demonstrated efficacy in a defined patient population, and carries a specific indication on its label.
- We've worked with researchers across hundreds of peptide-focused studies. The gap between understanding branded pharmaceuticals versus research-grade compounds comes down to three things most guides ignore: regulatory pathways, formulation consistency, and how approval status shapes both pricing and access.
- What's the difference between tesamorelin and Egrifta?
- Tesamorelin is the active pharmaceutical ingredient. A 44-amino-acid peptide that stimulates endogenous growth hormone release by binding to GHRH receptors in the anterior pituitary. Egrifta is the FDA-approved brand-name product containing tesamorelin acetate as its active compound. The chemical structure, mechanism of action, and biological effects are identical. The difference lies in regulatory approval, manufacturing oversight, formulation standardisation, and the clinical indication listed on the product label.
- The confusion around tesamorelin versus Egrifta stems from how pharmaceutical branding creates perceived separation between a compound and its commercial form. Egrifta is not a different peptide. It's tesamorelin packaged, tested, and distributed under FDA oversight with batch-to-batch quality verification. Research-grade tesamorelin, supplied by entities like Real Peptides, contains the same 44-amino-acid sequence synthesised through solid-phase peptide synthesis (SPPS) but lacks FDA approval as a finished drug product. This article covers the regulatory distinction between branded and research-grade tesamorelin, the mechanism of action both share, and what those differences mean for researchers evaluating compound sourcing.